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Breast cancer is the most common cancer in women (Stewart &
Wild, 2014). Among invasive breast cancers, 75% express the estrogen
receptor (ER) and 20–30% overexpress the human epidermal growth
factor receptor 2 (HER2). These patients can beneﬁt from therapy that
targets ER or HER2, resulting in superior overall survival (OS) in both
the curative and non-curative setting (Blamey et al., 2010; Gibson,
Dawson, Lawrence, & Bliss, 2007; Swain et al., 2015). However, there
is still a need to improve disease outcome, leading to a constant search
for new drug targets. In recent studies, the androgen receptor (AR) has
shown interesting potential as a drug target in breast cancer.
In prostate cancer, AR is a key driver of proliferation, and AR-
targeted drugs are currently part of standard care (Parker, Gillessen,
Heidenreich, & Horwich, 2015). Interestingly, AR is considered to be
overexpressed in 70–90% of breast cancers, including up to 30% of the
triple negative breast cancers (TNBC), and tumor response has been ob-
served following AR-directed therapy (Collins et al., 2011). This makes
AR a potentially interesting drug target for many breast cancer patients.
However, AR status is not routinely assessed in breast tumors. Cur-
rently, for immunohistochemical analysis, a broad range of cut-off
values is used, and AR status is determined by various antibodies. This
variance makes it difﬁcult to interpret the role of AR based on expres-
sion data obtained with immunohistochemistry (IHC) in breast cancer.
Therefore, pooled analyses using gene expression data to determine
the association between AR status and disease-free survival (DFS) and
OS in breast cancer patients is of interest. To address this, we ﬁrst per-
formed a literature review to summarize preclinical and clinical data
concerning the role of AR in breast cancer, including its role in physiol-
ogy, and its use in targeted therapy in prostate cancer. In addition, we
explored the prognostic value of the AR in breast cancer subgroups
using mRNA data of 7270 primary breast cancer samples obtained
from the public domain.
2. Search strategy
PubMed was searched for articles published until August 2018 with
the terms ‘androgen receptor’, ‘expression’, ‘cancer’, ‘molecular imag-
ing’, and ‘tumor’ in various combinations. Only articles in English were
reviewed. The abstracts were screened for relevance. We included
in vitro studies with breast cancer cell lines and in vivo and clinical stud-
ies using androgens or AR-targeted drugs. Outside of PubMed, we
searched abstracts of annual meetings of the American Society of Clini-
cal Oncology and the San Antonio Breast Cancer Symposium in
2014–2018 with the same terms. Finally, ClinicalTrials.gov was
searched for AR-targeted therapy trials in breast cancer patients.
3. Physiological function of AR
AR is expressed in hair follicles, bone, brain, liver, cardiovascular, and
breast tissue in both sexes and inmales also in testes and prostate tissue
(Kimura, Mizokami, Oonuma, Sasano, & Nagura, 1993). AR belongs to
the type I nuclear receptors. These receptors are intracellular transcrip-
tion factors that directly regulate gene expression in response to their li-
gand. Androgens are ligands that bind to the AR, and are produced in
ovaries of women, the prostate and testes of men, and by hair follicles
and the zona reticularis of the adrenal glands of both sexes (Burger,
2002;Wilson, 2011;Wilson & French, 1976). After the lipophilic andro-
gens diffuse through the cell membrane into the cytoplasm they bind to
intracellular AR. This leads to dissociation of heat shock proteins
followed by activation and dimerization of AR. The AR dimer then trans-
locates to the nucleus. Binding of the AR dimer to the androgen re-
sponse element in the promoter and enhancer regions of target genes
leads to upregulation or downregulation of DNA transcription. Depend-
ing on tissue type this leads to cell division, differentiation, apoptosis,
proliferation, or angiogenesis (Fig. 1).Female AR knockoutmice experience impaired follicular growth and
dysfunctional ovulation, illustrating that AR is essential for normal fe-
male fertility (Walters, Simanainen, & Handelsman, 2010). In women,
low serum androgen levels lead to reduced libido, reduced muscular
strength, and vaginal dryness, whereas high levels result in hirsutism,
a lower voice, and acne (Bachmann, 2002; van Staa & Sprafka, 2009).
Germline AR mutations result in androgen insensitivity syndromes,
which cause disorders in secondary sex characteristics such as
clitoromegaly, absence of internal genital structures, or presence of tes-
tes in phenotypic women (Quigley et al., 1992).
In men, low serum androgen levels are associated with depression
and can lead to low libido and erectile dysfunction, whereas high levels
have been linked to aggressive behavior (Buvat, Maggi, Guay, & Torres,
2013; Pope Jr, Kouri, & Hudson, 2000). Cardiovascular disease and coag-
ulation abnormalities have also been related to high doses of androgens
used in men, but these effects have not been reported in women
(Ferenchick, Hirokawa, Mammen, & Schwartz, 1995; Gooren, Wierckx,
& Giltay, 2014).
4. Mechanism of AR-targeted therapy in prostate cancer
The AR signaling cascade can be inhibited for therapeutic use in sev-
eral ways. Firstly, it can be inhibited indirectly by androgen deprivation
therapy by lowering circulating androgen levels. This can be done with
drugs such as luteinizing hormone-releasing hormone (LHRH)-agonists
or CYP17A1 inhibitors like abiraterone acetate, or by orchidectomy
(Table 1). In metastatic prostate cancer patients, the addition
of abiraterone acetate to prednisone resulted in a median OS of
15.8 months for the combination versus 11.2 months for prednisone
alone (Fizazi et al., 2012).
Secondly, the AR can be directly blocked by administering AR antag-
onists. Theﬁrst-generation AR antagonists approved by theUS Food and
Drug Administration and EuropeanMedicines Agency are bicalutamide,
ﬂutamide, and nilutamide, which inhibit the effects of autocrine testos-
terone production by the tumor. Unlike these AR antagonists, the
second-generation AR antagonist enzalutamide not only competitively
binds to the AR ligand-binding domain, but also inhibits nuclear trans-
location of AR, DNA binding, and coactivator recruitment (Tran et al.,
2009).
Thirdly, degradation of AR serves as a novel strategy for interfering
the AR signaling. The AR degraders such as ARV-330 are currently in
preclinical development (Teply & Antonarakis, 2016).
5. Mechanisms of actions of AR in breast cancer
5.1. Preclinical evidence
In vitro the androgens testosterone and dihydrotestosterone (DHT)
mainly reduced proliferation, while AR antagonists stimulated prolifer-
ation of ER-positive/AR-positive breast cancer cell lines (Andò et al.,
2002; Aspinall, Stamp, Davison, Shenton, & Lennard, 2004; Birrell
et al., 1995; Chottanapund et al., 2013; Cops et al., 2008; Macedo et al.,
2006; Ortmann et al., 2002; Poulin, Baker, & Labrie, 1988; Reese,
Warshaw, Murai, & Siiteri, 1988; Rizza et al., 2014; Szelei, Jimenez,
Soto, Luizzi, & Sonnenschein, 1997). However, increased proliferation
has been observed at very high androgen concentrations (100 nM-
1000 nM), especially in the extensively studied ER-positive/AR-positive
MCF-7 cell line (Aspinall et al., 2004; Lin et al., 2009; Lippman, Bolan, &
Huff, 1976; Maggiolini, Donzé, Jeannin, Andò, & Picard, 1999; Sonne-
Hansen & Lykkesfeldt, 2005). These proliferative effects of androgen
treatment observed at very high concentrations in ER-positive cell
lines might be due to conversion of DHT to the estrogen agonist 5α-
androstane-3β,17β-diol (Sikora et al., 2009). In addition, AR agonists
and AR antagonists both reduced tumor growth in in vivo ER-positive/
AR-positive breast cancer models (Boccuzzi et al., 1995; Cochrane






























Fig. 1.Effect of androgens on the androgen receptor (AR) in a physiological setting in an androgen-responsive cell. After free testosterone passively diffuses through the plasmamembrane,
it is converted to dihydrotestosterone (DHT) by 5α-reductase. In the cell, DHT binds to theAR,which leads to dissociation of heat shock proteins (HSPs), activation by phosphorylation (P),
and dimerization of the AR. The AR dimer then translocates to the nucleus, where it binds to the androgen response element in the promotor regions of target genes. The AR dimer-
androgen response element complex may act on the transcription machinery itself, or it recruits additional transcription factors or coregulators, ultimately leading to up- or
downregulation of DNA transcription. Depending on the tissue this might lead to cell division, differentiation, apoptosis, proliferation or angiogenesis.
Table 1
AR-targeted therapies in use as standard care.





Prostate cancer, endometriosis Suppresses luteinizing hormone and follicle stimulating hormone, which





Blocks conversion of precursors pregnenolone and
17α-hydroxypregnenolone into dehydroepiandrosterone and androstenediol





Metastatic prostate cancer Competes directly with
(dihydro-)testosterone for AR binding site
Second-generation
AR antagonists






Testosterone deﬁciency, breast cancer
in postmenopausal women
Binds directly to AR
Other Lixisenatide Diabetes mellitus type 2 Glucagon peptide agonist, little AR stimulation
AR, androgen receptor; LHRH, luteinizing hormone-releasing hormone.
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This phenomenon was also seen with ER-targeted therapy in breast
cancer patients. Although anti-estrogen therapy is the cornerstone of
endocrine therapy, high dose estrogenshave also induced tumor regres-
sion (Lewis-Wambi & Jordan, 2009).
In comparison to ER-positive/AR-positive breast cancer cell lines, an
opposite effect of androgens and AR antagonists is seen in in vitro ER-
negative/AR-positive cell lines. In these cell lines, androgens mainly
stimulated proliferation, while AR antagonists lowered proliferation
(Birrell et al., 1995; Cochrane et al., 2014; Doane et al., 2006; Hall,
Birrell, Tilley, & Sutherland, 1994; Lehmann et al., 2011; Naderi &
Hughes-Davies, 2008; Ni et al., 2011; Robinson et al., 2011). Also, in
in vivo ER-negative/AR-positive human breast cancer xenografts AR ag-
onists stimulated tumor growth while AR-antagonists inhibited
androgen-mediated growth of ER-negative/AR-positive breast tumors
(Lehmann et al., 2011; Ni et al., 2011).
Increased proliferation and cell survival has been associatedwith the
AR-mediated activation of the mitogen-activated protein kinase signal-
ing pathway (Lange, Gioeli, Hammes, & Marker, 2007). Simultaneous
stimulation of the epidermal growth factor receptor and AR
hyperactivated the mitogen-activated protein kinase pathway. In ER-
negative/AR-positive MDA-MB-231 cells this led to reduced prolifera-
tion, while stimulation of the epidermal growth factor receptor or AR
separately increased proliferation (Garay et al., 2012).Table 2
Breast cancer trials with newer AR-targeted drugs or combinations of AR-targeted and standar
Treatment Phase Subgroup Resu



















Orteronel II Metastatic AR+/ER+ breast
cancer
Stab






















Enzalutamide with or without aromatase
inhibitor






Abiraterone acetate plus prednisone with
or without exemestane versus
exemestane alone
II Metastatic ER+ breast cancer No d
a Results are only shown for patientswho tested positive for a biomarker for response to enza
beneﬁt rate; CI, conﬁdence interval; ER, estrogen receptor; HER2, human epidermal growth fac
progression-free survival; TNBC, triple-negative breast cancer.Crosstalk between AR and ER, where signal transduction of the ER
can affect the AR and vice versa, appears to increase proliferation.
These receptors can co-localize in breast cancer cells, as shown
with immunoﬂuorescence and immunoprecipitation (Migliaccio
et al., 2005; Peters et al., 2009). Interestingly, blocking the AR in
tamoxifen-resistant, ER-positive/AR-positive MCF-7 cells did restore
sensitivity to tamoxifen (De Amicis et al., 2010). In addition, an AR:
ER ratio ≥ 2 has been linked to an increased risk for failure while
on tamoxifen and a worse disease-speciﬁc survival in patients with
ER-positive breast cancer (Cochrane et al., 2014; Rangel et al.,
2018). This suggests that the AR:ER ratio may inﬂuence tumor re-
sponse to ER-targeted therapy.
Crosstalk between AR and HER2 has also been indicated. Testoster-
one exposure of MDA-MB-453 cells increased HER2 mRNA levels, and
exposure to the human epidermal growth factor receptor 3 (HER3) li-
gand heregulin increased bothHER2 and ARmRNA levels. Moreover, in-
hibition of HER2 signaling reduced androgen-stimulated cell growth in
ER-negative/HER2-positive/AR-positive cell lines (Naderi & Hughes-
Davies, 2008; Ni et al., 2011).
Crosstalk between AR and the Wingless proteins (Wnt) signaling
pathway has also been observed in ER-negative/AR-positive MDA-MB-
453 cells (Ni et al., 2011). Stimulation of AR with DHT directly upregu-
lated WNT7B mRNA levels, resulting in β-catenin activation. Nuclear
translocation of activated β-catenin stimulates HER3 transcription.d targeted therapies.
lts Adverse events Reference
HC ≥ 1%: 25% CBR at 16
ks
HC ≥ 10%: 33% CBR at 16
ks
Grade 3 fatigue in 3.1% (Traina et al.,
2018)
stable disease at 6
ths (95% CI 16.6–59.4%)
Grade 3 adverse events in 4% (Overmoyer
et al., 2015)
le disease at 3 months in
patients
Only grade 1 and 2 (Zweifel et al.,
2017)





Grade 3 hypertension in 2/8 patients (Rampurwala
et al., 2017)




(26%) CBR at 16 weeks
(11%) CBR at 24 weeks
Grade 3 dehydration in 1/19 (5%) (Bardia et al.,
2018)
breast cancer: 18%
1) CBR at 24 weeks
C: 33% (2/6) CBR at 16
ks
Only grade 1 and 2 (Gucalp et al.,
2017)
ian PFS 4.3 months (95%
1.0 – NA) in exemestane
ian PFS 16.5 months (95%
.9–10.9) in combination





% CBR at 24 weeks Any grade: fatigue (22.7%), nausea
(18.2%), diarrhea (13.6%), arthralgia
(13.6%)










Enzalutamide: grade 3/4 anemia (7%)
Combination: grade 3/4 hypertension




ifference in PFS Combination: grade 3/4 hypertension
(5.8%) and hypertension (5.8%)
(O'Shaughnessy
et al., 2016)
lutamide and had receivednoprior endocrine therapy. AR, androgen receptor; CBR, clinical
tor receptor 2; HR, hormone receptor; IHC, immunohistochemistry; NA, not available; PFS,
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PI3K/AKT pathway, resulting in cell proliferation (Ni et al., 2011).
In quadruple-negative breast cancer cell lines, comprising TNBC cell
lines without AR expression, androgens mostly did not affect prolifera-
tion, independent of the concentration (Aspinall et al., 2004; Barton
et al., 2015; Birrell et al., 1995; Lippman et al., 1976; Wang et al., 2011).
In conclusion, the effect of AR-targeted therapies differs according to
the ER status of breast cancer cells. Whereas androgens mainly inhibitFig. 2.Overview of studies on the prognostic value of AR expression measured immunohistoch
univariate Cox regression analysis. An orange bubble indicates an association between androge
(panel B). A blue bubble indicates an association between ARpositivity and shorter survival. The
value ≤ .05. ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; TNBC, tritumor growth in ER-positive breast cancer cell lines, they stimulate
tumor growth in ER-negative cell lines, and anti-androgens were most
effective in ER-negative/AR-positive cells. The effects of AR-targeted
drugs per breast cancer cell line are described in Supplementary
Table 1 (Andò et al., 2002; Aspinall et al., 2004; Barton et al., 2015;
Birrell et al., 1995; Chottanapund et al., 2013; Cochrane et al., 2014;
Cops et al., 2008; De Amicis et al., 2010; Doane et al., 2006; Garay
et al., 2012; Hackenberg et al., 1991; Hall et al., 1994; Lehmann et al.,emically per breast cancer subgroup. Associations have been studied using log-rank test or
n receptor (AR) positivity and prolonged disease-free survival (panel A) or overall survival
size of the bubble indicates the statistical signiﬁcance level. Black delineation indicates a P
ple-negative breast cancer.
140 C.M. Venema et al. / Pharmacology & Therapeutics 200 (2019) 135–1472011; Lin et al., 2009; Lippman et al., 1976; Macedo et al., 2006;
Maggiolini et al., 1999; Naderi & Hughes-Davies, 2008; Narayanan
et al., 2014; Ni et al., 2011; Ortmann et al., 2002; Poulin et al., 1988;
Reese et al., 1988; Rizza et al., 2014; Robinson et al., 2011; Sikora
et al., 2009; Sonne-Hansen & Lykkesfeldt, 2005; Szelei et al., 1997;
Wang et al., 2011).
5.2. Clinical evidence
The ovaries are a main source of androgens. Theoretically, this
means that LHRH analogues as well as oophorectomy, which are both
used in breast cancer patients with ER-positive tumors, likely result in
a reduction of androgen levels. In 13 premenopausal patients with ER-
positive breast cancer, androgen serum levels were lower following
treatment with the LHRH-analogue goserelin and an aromatase inhibi-
tor (Forward, Cheung, Jackson, & Robertson, 2004). Aromatase inhibi-
tors, also part of standard care for breast cancer patients with ER-
positive tumors, inhibit the conversion of androgens into estrogens. To






































































HR 1.61 (95% CI 1.16 - 2.22)

















































































Fig. 3. Disease-free survival curves for different thresholds for AR positivity in breast cancer s
positive and AR-negative cases in terms of disease-free survival, deﬁned as time of diagnos
conﬁdence intervals are shown for non-transparent curves. AR, androgen receptor; CI, conﬁd
HR, hazard ratio.inhibitors combined with androgen deprivation therapy in AR-positive
breast cancer patients. In a phase II study in 30 women with AR-
positive/triple negative metastatic breast cancer, androgen deprivation
by abiraterone acetate 1000mg once daily combinedwith prednisolone
5 mg twice daily resulted in one complete response and ﬁve patients
with stable disease (Bonnefoi et al., 2016).
Until recently, studies exploring the effect of AR-targeted therapy in-
cluded breast cancer patients regardless of tumor AR expression levels.
Non-tissue-selective androgens, such as testosterone propionate and
ﬂuoxymesterone, have been used for treatment of metastatic breast
cancer since the 1940s (Fels, 1944). High doses of androgens such as
ﬂuoxymesterone and testosterone administered to metastatic breast
cancer patients showed 19%and 36% tumor response rates, respectively,
without selection for AR expression. The treatment coincidedwithmas-
culinizing side effects such as acne, hirsutism, and lowering of the voice
in 15–20% of patients (Adair & Herrmann, 1946; Goldenberg,
Waters, Ravdin, Ansﬁeld, & Segaloff, 1973; Ingle et al., 2006, 1991;
Kellokumpu-Lehtinen,Huovinen, & Johansson, 1987). Testosteronepro-

















































































































ubgroups. Non-transparent curves show the threshold discriminating best between AR-
is to locoregional or distant recurrence, or death. Hazard ratios and corresponding 95%
ence interval; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2;
141C.M. Venema et al. / Pharmacology & Therapeutics 200 (2019) 135–147cancer, refractory to ER-targeted therapy, resulted in a complete or par-
tial tumor response in nine out of 53 patients and a median OS of
12months (Boni et al., 2014). A retrospective analysis evaluated the re-
sponse to ﬂuoxymesterone in 103 patients with metastatic, ER-positive
breast cancer and showed that 33 patients discontinued treatment due
to side effects. A clinical beneﬁt, deﬁned as objective tumor response or
stable disease ≥6 months was seen in 43% of remaining patients (Kono
et al., 2016).
Direct blocking of AR in breast cancer patients was ﬁrst described in
1988. Flutamide, 750 mg orally daily administered, resulted in one par-
tial tumor response and ﬁve stable diseases out of 29 patients, but was
accompanied by gastrointestinal side effects (Perrault et al., 1988). In
postmenopausal women, two out of 14 patients experienced disease
stabilization for 20–26 weeks when treated with the AR antagonist
nilutamide 100 mg orally per day (Millward, Cantwell, Dowsett,
Carmichael, & Harris, 1991). Due to the side effects and modest results
observed in clinical trials, the interest for AR-targeted therapy in breast
cancer diminished. However, with novel AR-targeted drugs emerging in






























AR-negativeHR 0.75 (95% CI 0.60 - 0.93)





























HR 0.76 (95% CI 0.55 - 1.07)














































































Fig. 4.Overall survival curves for different thresholds for ARpositivity in breast cancer subgroups
AR-negative cases in terms of overall survival, deﬁned as time of diagnosis to death by any cause
curves. AR, androgen receptor; CI, conﬁdence interval; ER, estrogen receptor; HER2, human epAR expression in breast cancer, AR-targeted therapy in breast cancer
has regained attention in recent years.
The ﬁrst study to select patients based on AR expression evaluated
the efﬁcacy of the AR blocker bicalutamide 150 mg per day orally in
26 postmenopausal women with ER-negative (IHC positivity ≤10%
tumor cells), progesterone receptor (PR)-negative, AR-positive (IHC
≥ 10%) metastatic breast cancer. A clinical beneﬁt rate was seen in 19%
of patients, while the drug was well tolerated (Gucalp et al., 2013).
However, most patients in this study were heavily pre-treated, which
may explain the low overall response rate. One case study reported a
complete response to bicalutamide in a womanwith AR-positive meta-
static breast cancer (Arce-Salinas, Riesco-Martinez, Hanna, Bedard, &
Warner, 2016).
More recently, studies have been performed with newer AR-
targeted drugs such as second-generation AR antagonists, AR modula-
tors and novel non-steroidal CYP17A1 inhibitors (Table 2) (Bardia
et al., 2018; Gucalp et al., 2017; Krop et al., 2018, 2017; O'Shaughnessy
et al., 2016; Overmoyer et al., 2015; Rampurwala et al., 2017;






























HR 1.34 (95% CI 0.66 - 2.69)






























































. Non-transparent curves show the threshold discriminating best betweenAR-positive and
. Hazard ratios and corresponding 95% conﬁdence intervals are shown for non-transparent
idermal growth factor receptor 2; HR, hazard ratio.
142 C.M. Venema et al. / Pharmacology & Therapeutics 200 (2019) 135–147Zweifel et al., 2017). A phase II study assessed the efﬁcacy of the second-
generation AR antagonist enzalutamide 160 mg per day in 118 patients
with locally advanced or metastatic, AR-positive (IHC N 0%), TNBC (ER/
PR IHC b 1%). Clinical beneﬁt rates were 25% at 16 weeks and 24% at
24 weeks. In patients whose tumors expressed ≥10% nuclear AR (n =
78), determined using antibodies optimized for measuring AR expres-
sion in breast cancer tissue (Kumar et al., 2017), clinical beneﬁt rates
were 33% at 16weeks and 22% at 24 weeks. Enzalutamide waswell tol-
erated,with fatigue being the only grade 3 side effect occurring in N2% of
patients (3.1%) (Traina et al., 2018). Results of the selective ARmodula-
tor enobosarm are also of interest: stable disease for N6 months has
been reported in up to 35% of heavily pre-treated patients
(Overmoyer et al., 2015). Furthermore, combinations of AR-targeted
therapy with hormonal or anti-HER2 therapy are currently being inves-
tigated. A phase II study evaluated the effect of exemestane with
enzalutamide in 247 patients with hormone receptor-positive/HER2-
negative, metastatic breast cancer. In the patients that had received no
prior endocrine therapy formetastatic breast cancerwho tested positive
for a gene expression-based biomarker for response to enzalutamide (n
= 50), exemestane/enzalutamide signiﬁcantly improved median
progression-free survival from 4.3 months (95% conﬁdence interval
[CI] 11.0 – NA) to 16.5 months (95% CI 1.9–10.9) compared to
exemestane/placebo (Krop et al., 2018). Ongoing trials with AR-
targeted therapy in breast cancer are listed in Supplementary Table 2.6. AR expression measured immunohistochemically in breast
cancers
Breast cancer patients with various tumor characteristics have expe-
rienced clinical beneﬁt from AR-targeted therapies. However, selecting
patients for such therapies has been challenging. Clear guidelines on
IHC interpretation of the AR have not been established thus far. Most
studies use IHC to determine AR expression and base their cut-off
value on 10% tumor cells staining positive. Data concerning the re-
sponse to AR-targeted therapies in patients with tumors expressing
low levels of AR, in the range of 1% to 10% positive cells by IHC, are
less frequently described. In the current setting of ER, even patients
with low ER expression (1–10%) are eligible for therapy, and guidelines
nowuse the 1% cut-off value (National Comprehensive CancerNetwork,
2018).
For AR measurements, different antibodies with varying sensitivity
and speciﬁcity have been used. Most experience in clinical breast cancerTable 3
Associations between ARmRNA expression and survival per breast cancer subgroups based on
Subgroup Univariate
Total (n) Events (n) HR 95% CI
Disease-free survival
Overall 4640 1335 0.87 0.82–0.91
ER-positive 2864 874 0.88 0.82–0.95
HER2-positive 743 303 1.12 1.00–1.25
ER-positive/HER2-positive 398 155 1.13 0.94–1.35
ER-positive/HER2-negative 2466 719 0.85 0.78–0.92
ER-negative/HER2-positive 345 148 1.10 0.96–1.26
ER-negative/HER2-negative 837 313 0.74 0.83–1.06
Overall survival
Overall 1427 336 0.87 0.78–0.96
ER-positive 972 208 0.84 0.71–0.98
HER2-positive 357 98 1.03 0.84–1.26
ER-positive/HER2-positive 165 43 0.90 0.63–1.27
ER-positive/HER2-negative 807 165 0.83 0.69–0.99
ER-negative/HER2-positive 192 55 1.08 0.85–1.36
ER-negative/HER2-negative 263 73 1.12 0.88–1.41
Associationswere determined using Cox regression analysis. Disease-free survival was deﬁned
to death by any cause. CI, conﬁdence interval; ER, estrogen receptor; HER2, human epidermal
a Adjusted for age, tumor size, grade, lymph node status, ER status, HER2 status and treatmetrials has been obtained with the AR441 mouse monoclonal IgG anti-
body from DAKO.
Studies on the role of AR in breast cancer have shown that AR posi-
tivity in the primary tumor is associated with better OS and DFS (Fig. 2
and Supplementary Table 3) (Agoff, Swanson, Linden, Hawes, & Lawton,
2003; Agrawal et al., 2016; Aleskandarany et al., 2016; Astvatsaturyan,
Yue, Walts, & Bose, 2018; Castellano et al., 2010; Choi, Kang, Lee, &
Bae, 2015; Elebro, Bendahl, Jernström, & Borgquist, 2017; Elebro et al.,
2015; Gong, Wei, Wu, Ueno, & Huo, 2014; Gonzalez-Angulo et al.,
2009; Gonzalez et al., 2008; He et al., 2012; Honma et al., 2013; R. Hu
et al., 2011; Hu, Chen, Ma, & Jiang, 2017; Jiang et al., 2016; Kensler
et al., 2018; Kraby et al., 2018; Li et al., 2017; Loibl et al., 2011; Luo,
Shi, Li, & Jiang, 2010; Micello et al., 2010; Niméus, Folkesson, Nodin,
Hartman, & Klintman, 2017; Park et al., 2012; Peters et al., 2012;
Pistelli et al., 2014; Rakha et al., 2007; Takeshita, Omoto, Yamamoto-
Ibusuki, Yamamoto, & Iwase, 2013; Tokunaga et al., 2013; Tsang et al.,
2014; Wenhui et al., 2014; Yu et al., 2011). This effect is most profound
in patients with ER-positive tumors. In patients with ER-negative breast
cancer, the relation between AR expression and disease outcome is less
clear, with the exception of TNBC where AR positivity has mainly been
associated with improved survival. In patients with HER2-positive tu-
mors, no signiﬁcant effect of AR expression on DFS or OS has been ob-
served, probably due to limited patient numbers.
Recently, a large study including 4417 women from the Nurses'
Health Study cohorts showed that AR-positivity (IHC N 1%) is associated
with improved breast cancer-speciﬁc survival in patients with ER-
positive breast cancer independent of clinicopathological characteristics
7 years after diagnosis (hazard ratio [HR] 0.53, 95% CI 0.41–0.69)
(Kensler et al., 2018). In contrast, AR positivity was associated with
worse breast cancer-speciﬁc survival in patients with ER-negative
breast cancer (HR 1.62, 95% CI 1.18–2.22). For patients with HER2-
positive breast cancer, AR positivity was not associated with breast
cancer-speciﬁc survival.
7. Retrospective pooled analysis of ARmRNA expression in breast
cancer
Given the limited available data on IHC, retrospective pooled analy-
ses using mRNA expression data is very interesting. Recently a meta-
analysis on gene expression data demonstrated that a higher AR
mRNA level is associated with favorable clinical outcome in women
with early-stage breast cancer (Bozovic-Spasojevic et al., 2017). This
analysis was based on intrinsic molecular subtypes, but in currenttumor receptor status.
Multivariatea
P Total (n) Events (n) HR 95% CI P
b0.001 927 314 0.96 0.85–1.08 0.49
b0.001 711 236 0.88 0.76–1.02 0.08
0.049 172 72 1.30 0.98–1.73 0.06
0.20 88 37 1.03 0.66–1.61 0.90
b0.001 623 199 0.89 0.76–1.05 0.17
0.17 84 35 1.46 1.03–2.06 0.03
0.31 132 43 1.02 0.73–1.42 0.92
0.008 632 153 1.02 0.79–1.23 0.80
0.026 472 107 0.90 0.72–1.13 0.37
0.77 119 39 1.34 0.95–1.89 0.10
0.55 55 20 0.81 0.46–1.60 0.46
0.035 417 330 0.94 0.72–1.13 0.66
0.53 64 19 1.72 1.08–2.73 0.021
0.35 96 27 1.12 0.73–1.72 0.59
at time to locoregional or distant recurrence, or death. Overall survival was deﬁned as time
growth factor receptor 2; HR, hazard ratio.
nt regimen.
Table 4
Associations between ARmRNA expression and survival in breast cancer intrinsic molecular subtypes.
Subgroup Univariate Multivariatea
Total (n) Events (n) HR 95% CI P Total (n) Events (n) HR 95% CI P
Disease-free survival
Luminal A 2009 548 0.97 0.87–1.07 0.51 462 126 0.98 0.79–1.22 0.86
Luminal B 922 367 0.87 0.78–0.98 0.018 219 99 0.76 0.61–0.94 0.014
Normal 355 118 0.85 0.66–1.09 0.20 46 18 1.93 0.81–4.59 0.14
HER2-enriched 253 111 1.04 0.88–1.22 0.68 87 38 1.31 0.89–1.94 0.17
Basal 507 191 1.05 0.81–1.36 0.72 113 33 1.04 0.57–1.92 0.89
Overall survival
Luminal A 711 109 0.87 0.68–1.10 0.24 325 52 1.16 0.82–1.64 0.41
Luminal B 327 106 0.87 0.70–1.08 0.22 125 51 0.64 0.45–0.91 0.014
Normal 100 32 0.79 0.50–1.27 0.34 25 9 2.75 0.44–17.28 0.28
HER2-enriched 130 50 1.17 0.91–1.49 0.22 70 23 1.76 1.10–2.82 0.019
Basal 159 39 1.03 0.54–1.97 0.94 82 18 0.98 0.37–2.65 0.98
Associationswere determined using Cox regression analysis. Disease-free survival was deﬁned at time to locoregional or distant recurrence, or death. Overall survival was deﬁned as time
to death by any cause. CI, conﬁdence interval; HER2, human epidermal growth factor receptor 2; HR, hazard ratio.
a Adjusted for age, tumor size, grade, lymph node status, estrogen receptor status, HER2 status and treatment regimen.
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used. Therefore, we used publicly available mRNA proﬁles to assess as-
sociations of predicted AR status and ARmRNA levels with disease out-
come in receptor status-based breast cancer subgroups and intrinsic
molecular subtypes (Parker et al., 2009).
We analyzed 7270mRNAexpression proﬁles of primary tumor sam-
ples of non-metastatic breast cancer patients, andwe assembled a refer-
ence group of 172 normal breast tissue samples obtained during
reduction mammoplasty. Whenever information on receptor status
was missing, we determined these by inference using gene expression
data. Detailed analysis methods information has previously been pub-
lished (Bense et al., 2017). Overall, ESR1mRNAand ERBB2 functional ge-
nomic mRNA expression (Fehrmann et al., 2015) clearly discriminated
between immunohistochemically determined positive and negative re-
ceptor statuses (Supplementary Fig. 1). AR status in the tumor samples
was considered positive when the ARmRNA level was above a certain
threshold. We explored multiple thresholds by calculating the 2.5th,
25th, 50th, 75th, and 97.5th percentiles of ARmRNA level in normal breast
tissue. Differences in survival between predicted AR-positive and AR-


























































Fig. 5. Scatter dot plot of standardized ARmRNA expression in breast cancer subgroups. ARmRN
like 2 (BL2), immunomodulatory (IM), luminal androgen receptor (LAR), mesenchymal (M), m
ER-negative/HER2-positive breast cancer subgroups. Whenever information on ER and HER2
bars indicate median mRNA expression and interquartile range. AR, androgen receptor; ER, estrank test. In addition, the association between AR mRNA levels and
DFS and OS in the tumors samples was determinedwith Cox regression.
For the group as a whole, DFS and OS were prolonged in patients
with AR-positive tumors in comparison to those with AR-negative tu-
mors (Figs. 3 and 4). The difference in survival was more pronounced
when lowering the thresholds deﬁning AR positivity (Supplementary
Figs. 2 and 3). Cox regression also showed that a higher AR mRNA
level was associated with prolonged DFS and OS in the whole group.
However, this association did not remain signiﬁcant when corrected
for relevant clinicopathological parameters (Table 3).
In patients with ER-positive/HER2-negative tumors, AR positivity
was also associated with a prolonged DFS, depending on the threshold
used (Figs. 3 and 4; Supplementary Figs. 2 and 3). We observed a simi-
lar, but less pronounced, trend for prolonged OS with AR positivity. A
higherARmRNA levelwas associatedwith prolongedDFS andOS in uni-
variate analyses. This association also did not remain signiﬁcant when
corrected for relevant clinicopathological parameters (Table 3).
For patients with ER-negative/HER2-positive and ER-positive/HER2-
positive tumors, AR positivity was associated with a shorter DFS (Figs. 3


























































A expression is shown for triple-negative breast cancer subtypes basal-like 1 (BL1), basal-
esenchymal stem-like (MSL), and unstable (US), and for ER-positive/HER2-negative and
status was missing, we determined these by inference using gene expression data. Error
rogen receptor; HER2, human epidermal growth factor receptor 2.
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3). In line with this observation, Cox regression showed that a higher
AR mRNA level was associated with shorter DFS and OS in patients
with ER-negative/HER2-positive breast cancer when corrected for rele-
vant clinicopathological parameters (Table 3).
For the intrinsicmolecular subtypes, a higher ARmRNA levelwas as-
sociated with prolonged DFS and OS in the luminal B subtype, indepen-
dent of other relevant clinicopathological parameters (Table 4). In the
HER2-enriched molecular subtype, a higher ARmRNA level was associ-
ated with shorter OS independent of clinicopathological parameters.
The results above suggest that the effect of AR status and ARmRNA
levels on DFS and OS varies between receptor status-based subgroups
as well as between intrinsic molecular subtypes.
We also explored mRNA expression of AR in breast cancer sub-
groups. Whereas AR expression was comparable in ER-positive/HER2-
negative and ER-negative/HER2-positive tumors, it was evidently
lower in ER-negative/HER2-negative tumors (Fig. 5). However, in the
luminal AR (LAR) TNBC subtype (Lehmann et al., 2011),ARmRNA levels
were similar to those found in ER-positive or HER2-positive tumors.
ESR1 and ERBB2 expression levels in the LAR subtype were similar to
other TNBC subtypes (Supplementary Fig. 4). Furthermore, in the ER-
negative/HER2-positive subgroup ARmRNA levels positively correlated
with HER2 (R 0.47, 95% CI 0.41–0.52) and HER3 mRNA levels (R 0.43,
95% CI 0.37–0.48). AR mRNA expression levels did not correlate with
Wnt or the more downstream c-Myc and β-catenin.8. Discussion and future perspectives
This review summarizes information on preclinical and clinical data
concerning the role of AR in breast cancer, as well as data on immuno-
histochemical and mRNA measurement of AR.
For further implementation of AR-directed therapy in breast cancer
insight in patient selection criteria seems to be critical. The associations
of ARmRNA levels with DFS and OS in the different ER and HER2 status-
based subgroups are in agreementwith the associations reported in cur-
rent literature based on IHC data. However, the association between
predicted AR positivity as well as a higher ARmRNA level and shorter
survival we observed in the ER-negative/HER2-positive subgroup and
the HER2-enriched intrinsic molecular subtype is in contrast with an-
other recent mRNA-based analysis (Bozovic-Spasojevic et al., 2017).
That analysis showed that a higher AR mRNA level is associated with
prolonged survival in the HER2-enriched molecular subtype. The dis-
crepancy indicates that the pooled analyses should be interpreted
with some caution as they are based on retrospective, publicly available
data that can contain potential confounders. However, based on our
analysis, targeting both HER2 and AR might be of interest for patients
with ER-negative/HER2-positive/AR-positive tumors. This is supported
by a currently ongoing trial in breast cancer patients with HER2-
positive/AR-positive tumors assessing the effect of trastuzumab plus
enzalutamide (NCT02091960). Preliminary results have shown a 24-
week clinical beneﬁt rate of 27.3% in patients who received a median
of four prior anti-HER2 therapies (Krop et al., 2017).
We used our retrospective pooled analysis as a hypothesis-
generating tool to facilitate insight into the role of AR in the context of
different breast tumor characteristics. Here, we aimed at detecting as
many potentially relevant observations with reasonable power, which
would considerably reduce if we had split our data for validation pur-
poses. As we pursued this hypothesis-generating approach, the results
of our pooled analysis require validation in larger and preferably pro-
spective patient cohorts.
The limited amount of data on AR expression in breast cancer sug-
gests that a discrepancy in AR status between primary and distant met-
astatic breast cancer lesions can exist in up to 33% of patients (D'Amato
et al., 2016). Obtaining a biopsy during the course of disease is currently
considered the gold standard, but is not always feasible. Furthermore, asingle biopsy from a metastatic lesion is not necessarily representative
for the patient's complete AR status.
A different approach to obtain potentially whole body information
about tumor hormonal receptor status is via circulating tumor cells or
circulating tumor DNA (Bidard et al., 2014; Kasimir-Bauer et al., 2016).
Also, whole body in vivo expression of ARwith intact ligand binding do-
main is possible by using molecular imaging of the AR with
18F-ﬂuorodihydrotestosterone positron emission tomography (PET).
This tracer showed selective uptake in prostate cancer metastases
and could be blocked by ﬂutamide and enzalutamide (Dehdashti
et al., 2005; Scher et al., 2012). In metastatic breast cancer patients,
18F-ﬂuorodihydrotestosterone tumor uptake showed good correlation
with IHC staining for AR in representative tumor biopsies (P= .01) of
13 patients (Venema et al., 2017).
Although the results of AR-targeted therapies in metastatic breast
cancer patients are interesting, all patients eventually showed progres-
sion while on treatment. Mechanisms that may be related to resistance
to AR-targeted therapies in metastatic prostate cancer include ampliﬁ-
cation or overexpression of AR, ligand-independent activation, overex-
pression of coactivators, and the expression of active AR splice variants
(Chen et al., 2004; Fujimoto, Mizokami, Harada, & Matsumoto, 2001;
Scher et al., 2010; Stanbrough et al., 2006; Teply & Antonarakis, 2016).
The most frequently studied AR splice variant in tumors and circulating
tumorDNAs in the context of prostate cancer is AR-V7, inwhichAR is ac-
tivated without ligand binding; this variant is predictive of resistance to
both enzalutamide and abiraterone (Antonarakis et al., 2014). Analysis
of different splice variants showed AR-V7mutations in 53.7% of primary
breast cancer samples (n= 54) (Hickey et al., 2015). The role of these
potential mechanisms for resistance to AR-targeted therapies in breast
cancer requires further study.
In summary, increased understanding of the role of AR in breast can-
cer, and optimal selection for AR-targeted therapies, can potentially im-
prove treatment options for breast cancer patients. With novel
(selective) AR antagonists becoming available along with new patient
selection methods, AR-targeted therapies deserve further evaluation
in clinical breast cancer studies. The response rates to AR-targeted ther-
apies in unselected patient populations are relatively low. Preclinical
and clinical data show that AR antagonists could be a potential therapy
for patients with ER-negative/AR-positive tumors. In addition, based on
our retrospective pooled analysis, patients with HER2-positive/AR-pos-
itive tumors might be a preferred subgroup to treat with combined
HER2-targeted and AR-targeted treatment. These data indicate that pa-
tient selection, using additional tumor characteristics, might increase
the role of AR-targeted therapy in patients with breast cancer.Conﬂicts of interest statement
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